GlaxoSmithKline News and Research

RSS

Unique open science project shows way for development of new antimalarial treatments

Malaria remains one of the world's leading causes of mortality in developing countries. Last year alone, it killed more than 400,000 people, mostly young children.

16 Sep 2016

GSK, VentureWise partner to deliver independent educational program on COPD to GPs

A new agreement between GlaxoSmithKline and VentureWise—part of the MedicineWise Group—will see an independent educational program delivered to GPs on the topic of chronic obstructive pulmonary disease.

29 Jul 2016

Better understanding of HIV latency could be key to eradicating virus, say researchers

A better understanding of HIV latency is the key to eradicating the virus researchers at the University of North Carolina and partner institutions write in a perspective in the journal Science.

22 Jul 2016

GSK and University of Leicester team up to develop novel drugs to treat blood cancer

A collaboration between the University of Leicester and global pharmaceutical company GlaxoSmithKline has been established to discover and develop novel medicines to treat aggressive forms of blood cancer.

21 Jul 2016

Study finds sex differences in smoking cessation with medications

A new study led by Assistant Medical Professor Philip Smith of The City College of New York's Sophie Davis Biomedical Education/CUNY School of Medicine, and conducted in collaboration with researchers at Yale University and Yeshiva University, found important differences between women and men in their ability to quit smoking when taking medications commonly prescribed to help smokers quit.

17 Jul 2016

Prospective biobank studies with genetic data can help improve drug development, reduce costs

With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?

15 Jun 2016

Darapladib drug can protect against vision loss in diabetic patients

Researchers at Queen's University Belfast and University College London have discovered that a drug, originally developed to treat cardiovascular disease, has the potential to reduce diabetes related blindness.

14 Jun 2016

New technique could help reduce chances of drug failure during later stages of clinical trials

An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline.

2 Jun 2016

AbbVie, Sanofi and Novo Nordisk listed among top 10 companies in 2016 UK Pharma RepTrak rankings

AbbVie, Sanofi and Novo Nordisk top the RepTrak® ranking of the most reputable pharmaceutical companies in the UK, Reputation Institute announced today, based on more than 1,600 ratings collected in the first quarter of 2016 from members of the UK general public.

1 Jun 2016

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the U.S.) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet.

25 Apr 2016

Cambridge Pharmaceutical Cryo-EM Consortium formed by FEI, five pharmaceutical companies, the Medical Research Council and the University of Cambridge

FEI (NASDAQ: FEIC) has partnered with five pharmaceutical companies: Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics, and UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB); and the University of Cambridge’s Nanoscience Centre, to form the “Cambridge Pharmaceutical Cryo-EM Consortium,” which is the first of its kind worldwide.

From Thermo Fisher Scientific – Electron Microscopy Solutions 4 Apr 2016

Johns Hopkins scientists develop antibody to curb lung tumor cell growth, breast cancer metastasis

Johns Hopkins scientists report they have developed an antibody against a specific cellular gateway that suppresses lung tumor cell growth and breast cancer metastasis in transplanted tumor experiments in mice, according to a new study published in the February issue of Nature Communications.

17 Mar 2016

WRAIR researchers publish results from Plasmodium vivax malaria vaccine study

Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.

27 Feb 2016

Two investigational Ebola vaccines well-tolerated in Phase 2 clinical trial

Two investigational vaccines designed to protect against Ebola virus disease were well-tolerated and induced an immune response among 1,000 vaccinated participants in the Phase 2 randomized, placebo-controlled clinical trial called PREVAIL I.

25 Feb 2016

FDA approves Lannett's ANDA for Sumatriptan Nasal Spray USP

Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray USP, 5 mg/spray and 20 mg/spray, the therapeutic equivalent to the reference listed drug Imitrex Nasal Spray, of GlaxoSmithKline.

22 Feb 2016

New visiongain report on Zika virus

What can be expected as the Zika outbreak progresses? Which areas are going to be the most affected? This visiongain report discusses the future direction of the Zika virus outbreak and the implications of its spread. It also discussed the infectious disease diagnostics market and the global human vaccines market, both of which are forecast to 2026.

22 Feb 2016

Mylan announces FDA's acceptance of ANDA filing for generic Advair Diskus

Mylan N.V. today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted for filing by the U.S. Food and Drug Administration.

22 Feb 2016

Clinical study shows new Ebola vaccine stimulates strong immune responses in adults

A clinical trial of a new Ebola vaccine (ChAd3-EBO-Z) that resulted from an unprecedented global consortium assembled at the behest of the World Health Organization has found that it is well tolerated and stimulates strong immune responses in adults in Mali, West Africa and in the US, according to a study published in the latest issue of the journal Lancet Infectious Disease.

19 Nov 2015

NIAID launches major initiative to advance novel approaches to treat, prevent HIV infections

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, launched a major initiative to advance novel approaches to treat and prevent HIV infections based on broadly neutralizing antibodies (bNAbs) today.

19 Nov 2015

Nucala (mepolizumab) approved for treatment of asthma patients

The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.

5 Nov 2015

GlaxoSmithKline News and Research

Unique open science project shows way for development of new antimalarial treatments

GSK, VentureWise partner to deliver independent educational program on COPD to GPs

Better understanding of HIV latency could be key to eradicating virus, say researchers

GSK and University of Leicester team up to develop novel drugs to treat blood cancer

Study finds sex differences in smoking cessation with medications

Prospective biobank studies with genetic data can help improve drug development, reduce costs

Darapladib drug can protect against vision loss in diabetic patients

New technique could help reduce chances of drug failure during later stages of clinical trials

AbbVie, Sanofi and Novo Nordisk listed among top 10 companies in 2016 UK Pharma RepTrak rankings

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Cambridge Pharmaceutical Cryo-EM Consortium formed by FEI, five pharmaceutical companies, the Medical Research Council and the University of Cambridge

Johns Hopkins scientists develop antibody to curb lung tumor cell growth, breast cancer metastasis

WRAIR researchers publish results from Plasmodium vivax malaria vaccine study

Two investigational Ebola vaccines well-tolerated in Phase 2 clinical trial

FDA approves Lannett's ANDA for Sumatriptan Nasal Spray USP

New visiongain report on Zika virus

Mylan announces FDA's acceptance of ANDA filing for generic Advair Diskus

Clinical study shows new Ebola vaccine stimulates strong immune responses in adults

NIAID launches major initiative to advance novel approaches to treat, prevent HIV infections

Nucala (mepolizumab) approved for treatment of asthma patients

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News